Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Lin

Showing results (721-730 of 792) with videos related to

Pageof 80
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinomaLiz Y Han, Mavis S Fletcher, Diana L Urbauer, et al.
Journal of the National Cancer Institute|January 10, 2008
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liverMichael J Gray, George Van Buren, Nikolaos A Dallas, et al.
Psychiatric Genetics|August 13, 2009
Long tandem repeats as a form of genomic copy number variation: structure and length polymorphism of a chromosome 5p repeat in control and schizophrenia populationsHeather A Bruce, Nancy Sachs, Dobrila D Rudnicki, et al.
Cancer Biology & Therapy|December 17, 2009
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma modelsChunhua Lu, Mian M K Shahzad, Myrthala Moreno-Smith, et al.
Clinical Immunology (Orlando, Fla.)|September 12, 2015
Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:CDiane M Da Silva, Andrew W Woodham, Joseph G Skeate, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 10, 2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
ESMO Open|June 5, 2026
Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)H Chen, H Xu, Z Yin, et al.
International Journal of Cancer|December 6, 2008
Functional significance of VEGFR-2 on ovarian cancer cellsWhitney A Spannuth, Alpa M Nick, Nicholas B Jennings, et al.
Journal of the National Cancer Institute|March 4, 2008
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growthWilliam M Merritt, Yvonne G Lin, Whitney A Spannuth, et al.
Pageof 80

Showing results (721-730 of 792) with videos related to

Sort By:
Pageof 80
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinomaLiz Y Han, Mavis S Fletcher, Diana L Urbauer, et al.
Journal of the National Cancer Institute|January 10, 2008
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liverMichael J Gray, George Van Buren, Nikolaos A Dallas, et al.
Psychiatric Genetics|August 13, 2009
Long tandem repeats as a form of genomic copy number variation: structure and length polymorphism of a chromosome 5p repeat in control and schizophrenia populationsHeather A Bruce, Nancy Sachs, Dobrila D Rudnicki, et al.
Cancer Biology & Therapy|December 17, 2009
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma modelsChunhua Lu, Mian M K Shahzad, Myrthala Moreno-Smith, et al.
Clinical Immunology (Orlando, Fla.)|September 12, 2015
Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:CDiane M Da Silva, Andrew W Woodham, Joseph G Skeate, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 10, 2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
ESMO Open|June 5, 2026
Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)H Chen, H Xu, Z Yin, et al.
International Journal of Cancer|December 6, 2008
Functional significance of VEGFR-2 on ovarian cancer cellsWhitney A Spannuth, Alpa M Nick, Nicholas B Jennings, et al.
Journal of the National Cancer Institute|March 4, 2008
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growthWilliam M Merritt, Yvonne G Lin, Whitney A Spannuth, et al.
Pageof 80